SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : North American Vaccine
NVX 0.986-5.2%Jan 30 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don W Stone who wrote (183)12/24/1997 8:43:00 AM
From: Don W Stone  Read Replies (1) of 507
 
Close, as in VERY

Those that i talk to are up , highly confident that approval will come, but uncertain on just WHEN. Today , next week, first week in january.

I am told that a Tucker Anthony technical analyst has the stock going to 35 or better on approval.

There are those of us who think NVX just may get more than just an approval. After all, the clinical trials show that NVX's vaccine is better than any of the other DTaP vaccines now on the market. The data that the FDA has would allow them to reach the conclusion that CERTIVA is more effective in controlling the pertussis disease than any of the DTaP vaccines that they have approved ( reference the Swedish study) and that it is the only DTaP vaccine that has elicited NO ADVERSE EVENTS .
In any event NVX/Abbott will not have any trouble with getting this product to the market. Leadtime? hogwash.Those that think otherwise are fools.

NVX will be up from here in'98, BIGTIME. :-}, :-}, :-}

Here's for a HAPPY HOLIDAY to all. :-}
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News